Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 30 of 46

Results: Head-to-Head Comparisons of DMARDs

In the two trials comparing D-penicillamine and hydroxychloroquine, methotrexate (MTX) was not given to either treatment group. No statistically significant differences between groups were found in disease activity or inflammation. Health status was not reported.

Sulfasalazine and hydroxychloroquine were compared in patients who did not receive MTX. The DMARDs produced similar outcomes in disease activity and inflammation levels, but no statistical analysis was reported. Health status was not reported.

Leflunomide and methotrexate were compared, but no statistically significant differences in disease activity, health status, or inflammation levels were noted.

Etanercept and infliximab were compared in patients who could also receive MTX. No statistically significant differences in disease activity, health status, or inflammation levels were noted.